Gregg Semenza, MD, PhD: The Role of HIF-1 and HIF-2 in Cancer

Gregg L. Semenza, MD, PhD, was recently awarded the Nobel Prize in Physiology or Medicine for his groundbreaking work in isolating hypoxia inducible factor (HIF) 1, which controls genes that are involved in cells' adaptation to low oxygen levels, with implications for cancer, ischemia, and chronic lung disease. In this interview with i3 Health, Dr. Semenza discusses the involvement of HIF-1 and HIF-2 in cancer and shares insights on the progress that is being made in developing HIF-1 and HIF-2 i...
Continue reading

Professional Oral Care for Everolimus-Induced Oral Mucositis: Naoki Niikura, MD, PhD

In combination with exemestane, everolimus is an effective treatment for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. However, this treatment can often cause oral mucositis. This serious adverse event, characterized by the formation of ulcers, can cause difficulty in swallowing and speaking, necessitating dose reduction and treatment disruption if not properly managed. In their study now published in The Oncologist, Naoki Nii...
Continue reading

Strategies to Optimize Multiple Myeloma Treatment With Carol Ann Huff, MD

Because multiple myeloma frequently remains asymptomatic until the disease is in the advanced stages, it can be difficult to diagnose and has limited treatment options, resulting in a five-year survival rate of only 50.7%. In this Q&A session from i3 Health's live meeting series, Evolving Treatment Paradigms in Multiple Myeloma and Implications for Shared Decision Making, Carol Ann Huff, MD, Medical Director for the Johns Hopkins Kimmel Cancer Center, discusses strategies to enhance the trea...
Continue reading

Durvalumab Plus Platinum/Etoposide for Extensive-Stage SCLC: Luis Paz-Ares, MD

Because most patients with small-cell lung cancer (SCLC) present with extensive-stage disease—in which the cancer has spread to both lungs or throughout the body—survival rates are poor, and there is a need to develop alternative treatments to improve outcomes. In their study now published in The Lancet, Luis Paz-Ares, MD, and colleagues found that in patients with extensive-stage SCLC (ES-SCLC), the addition of the immunotherapy drug durvalumab to a chemotherapy regimen of platinum/etoposide si...
Continue reading

Finding Solutions in Advanced NSCLC Without Driver Mutations: Jamie E. Chaft, MD

​Many patients with non-small cell lung cancer (NSCLC) present with advanced disease, which is highly resistant to chemotherapy. Recently, the use of tumor histology and relevant molecular biomarkers in determining optimal treatment strategies has improved outcomes for some patients, yet a number of targeted therapies are not applicable to patients without driver mutations. In this interview with i3 Health, Jamie E. Chaft, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center and an...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.